Policy outcomes
How this issue is resolved shapes the rules voters live under.
The issue in plain English
Should marijuana be legalized at the federal level?
Federal lawmakers face growing pressure to reconcile U.S. drug law with state policies and shifting public opinion on marijuana. Supporters argue legalization would generate tax revenue, ease enforcement burdens and align law with practice, while opponents warn of public-health risks and uncertainty about long-term social effects.
Why this matters
What the answer actually changes.
Representation
The arguments reveal who gets a stronger voice when the question is settled.
Trust
Whether the process feels fair influences how voters trust the outcome.
The arguments
Two sides of the debate.
The goal is not to decide for the voter. It is to make the strongest competing views easy to understand.
Supporters say
The case for federal legalization
Supporters say federal legalization would resolve conflicts between state and national law, give cannabis businesses access to banking and standard tax treatment, and allow interstate commerce and quality regulation. The Congressional Research Service has estimated that federal marijuana taxes could generate roughly $8.5 billion a year, money that proponents say could fund treatment, enforcement of remaining rules or general revenue needs. Advocates also argue that legalization would reduce arrests for low-level possession, which have historically fallen disproportionately on Black and Hispanic Americans according to studies cited by the American Civil Liberties Union. They contend that regulating marijuana like alcohol would replace illicit markets with licensed sellers, enable age limits and product testing, and expand scientific research that has been hampered by Schedule I status.
Critics say
The case against federal legalization
Opponents point to research from the National Institute on Drug Abuse linking heavy marijuana use to cognitive impairment, dependence and elevated risks of anxiety, depression and psychosis, particularly among adolescents and frequent users of high-potency products. They warn that federal legalization could normalize use, expand commercial marketing and lead to higher rates of impaired driving and emergency-room visits, citing data from some states that have legalized. Critics, including some law-enforcement groups and addiction-medicine organizations, also argue that legalization is premature given limited long-term studies on today's more potent cannabis products. They say states should remain the primary laboratories for policy and that rescheduling or targeted reforms — rather than full legalization — could address research and medical-access concerns without committing the federal government to a nationwide commercial market.
Key facts
Numbers behind the question.
Schedule I
Federal classification of marijuana since 1970, alongside heroin and LSD
Controlled Substances Act
24 states + D.C.
Have legalized recreational marijuana as of 2024; 38 states allow medical use
State statutes compiled by NCSL
70%
Share of U.S. adults supporting legalization in 2023, up from 12% in 1969
Gallup
~$8.5 billion
Estimated potential annual federal marijuana tax revenue under legalization
Congressional Research Service
Context
Where federal and state law diverge
Marijuana has been a Schedule I controlled substance since 1970, placing it alongside heroin and LSD under federal law and restricting research, banking access and interstate commerce for cannabis businesses. Yet 24 states and the District of Columbia have legalized recreational use and 38 states allow medical use, creating a patchwork in which conduct that is legal under state law can still violate federal statutes. In 2024 the Drug Enforcement Administration began a formal rulemaking process to move marijuana from Schedule I to Schedule III, a step that would loosen but not eliminate federal restrictions. That proposal has not been finalized, and Congress has not passed legislation to fully legalize the drug at the federal level. Public opinion has shifted markedly, with Gallup reporting 70 percent support for legalization in 2023, compared with 12 percent in 1969.
Evidence
What the data show
Tax and revenue projections vary widely depending on assumed federal excise rates and market size; the Congressional Research Service's roughly $8.5 billion annual estimate is one of several scenarios, and state experiences show revenues can fall short of early forecasts as prices decline. States that legalized earliest, such as Colorado and Washington, have reported both increased tax collections and increases in some cannabis-related health indicators, including emergency visits tied to high-potency products. Research on health effects is still developing. NIDA and the National Academies of Sciences, Engineering and Medicine have found evidence of therapeutic benefits for certain conditions, such as chronic pain and chemotherapy-induced nausea, alongside risks associated with heavy or adolescent use. Federal Schedule I status has historically limited the volume of U.S.-based clinical research, a constraint that rescheduling could partially ease.
Continue exploring
Keep going.
Issue brief
Should the Electoral College Be Abolished?
Americans remain divided over whether to keep the constitutional system that has chosen presidents since 1789.
Issue brief
Did Reaganomics deliver on its promises?
Four decades on, the economic record of the Reagan era remains a contested benchmark in American policy debates.
Issue brief
Should Citizens United be overturned?
More than a decade after the Supreme Court reshaped campaign finance, Americans remain divided over whether the ruling should stand.
Issue brief
Should the federal minimum wage rise to $15 an hour?
Lawmakers and economists continue to debate whether more than doubling the $7.25 federal floor would lift workers out of poverty or cost jobs.